Beyond the Mag 7 – the trillion dollar club has more members than most investors realise. In this episode of Livewire’s Buy Hold Sell Vihari Ross puts seven of the world’s largest companies to the test. From AI-driven structural growers to legacy businesses quietly reinventing themselves, there are compelling opportunities hiding in plain sight if you know where to look.
Transcript
Tom: Hello and welcome to Livewire Buy Hold Sell. I’m Tom Stelzer. When you think about the world’s biggest stocks, it’s hard to look past the old concrete Mag 7. But what about the other companies in the trillion dollar club or knocking on its door? Joining me today are Vihari Ross from Antipodes and Casey McClean from Magellan to offer their take on the world’s other biggest companies and share a global large cap pick of their own. Guys, thanks for joining us.
Vihari/Casey: Thanks Tom. TSMC (TPE: 2330)
Tom: We’re going to start with one of the world’s hottest companies right now TSMC, the Taiwanese chipmaker. Vihari, I’ll come to you first. Is that a buy or a sell?
Vihari: This is a buy. I think this is a stock that, historically speaking, was very high quality but was cyclical. With the advent of AI and clearly the leading edge technology that TSMC has, it has transitioned to a more structural grower. This is a stock trading at less than 20 times multiple, growing its AI revenues at 60%, with the overall business growing at 25% per annum – very compellingly valued. As they become more advanced, they’re able to shed some of their lower quality chips to other companies that are happy to take that revenue off their hands, and they’re getting a mix and pricing benefit that’s very material and significant. Very much a buy.
Tom: I think it’s up about 94% over the last year, almost 20% this year alone. Casey, what about you? Is it a buy or a sell?
Casey: I think TSMC is a buy. It’s probably one of – or maybe the most important company in the world, and that’s really because of that near monopoly position they have in leading edge chips, which means they’re the facilitator of the AI revolution, but really all tech innovation as well. What we like about them is they’re not dependent on one customer, one product, or even one theme. They’re everybody’s foundry and growing really fast. In fact, they just recently raised their medium-term revenue growth to about 25%.
We think that’s comfortable when you think about their expanding customer base. It’s not just Nvidia doing GPUs, it’s other fabless companies like AMD, it’s the hyperscalers like Google doing their own chips, and AI chips are expanding into new product areas like autonomous vehicles as well. If you’re growing at 25% and only trading around 20 times, that looks pretty attractive. They’re very similar numbers to what you get with Nvidia, except with Nvidia you have to accept the market share risk that new customers are coming in to try and take their near monopoly position, which could also lead to some pricing pressure.
Berkshire Hathaway (NYSE: BRK.B)
Tom: Next up is Berkshire Hathaway. Casey, I’ll stay with you. We’re in the post-Warren Buffett era, but is it a buy, hold, or sell?
Casey: I think Berkshire is a buy, and you’re right it’s just gone through the biggest change in their history with Warren stepping down after 60 years. But we think with Greg Abel, we’re in a pretty safe pair of hands. He’s been there for decades and has been groomed for this position for a long time. We’re not looking for any drastic change in the company’s strategy. It’s really going to be about that decentralised model where the 51 non-insurance companies they have will continue to act with autonomy, whilst they maintain their four core holdings of Apple, Coke, Moody’s and American Express. They’re sitting on a massive pile of dry powder – $373 billion in cash – which they’re going to deploy whenever there’s a market panic or one of those famous fat pitches comes along, which makes it pretty defensive. We’ve seen that because Abel has immediately turned back on the buyback. It’s a pretty unique company with their low cost of funds, and valuation is reasonable, especially if we do see the insurance cycle turn.
Tom: Vihari, what about you. Buy or sell on Berkshire?
Vihari: This is a sell for me. I have a different opinion here. I think you’re paying 1.4 to four times book for this business, and 40% of the valuation is in cash. I think you only own this stock if you’re a massive bear on markets. Not only is there 40% in cash, another third of the value is in these equity investments. Buffett himself has said how difficult it has been to redeploy that money. And on the insurance business, they only intend to make money from the float. So certainly if you want to buy an insurance business, there are cheaper insurance businesses to buy. A number of the stocks in their stable are frankly overvalued.
Eli Lilly (NYSE: LLY)
Tom: Vihari, I’ll stay with you. We’re going to look at the world’s largest pharmaceutical company, Eli Lilly. Is that a buy or sell?
Vihari: This is a sell. This is a pharmaceutical company that has been valued very exuberantly off a vision of singular success in GLP-1s. More than 90% of its valuation is coming from a vertical where there is competition and this weird asymmetry if you have high pricing, not as many people can access the product; if you have lower pricing, more people can access it, but then you don’t reach your total addressable market. One of the unfortunate realities here is access, not only in terms of getting rebated access to the drugs, but also the fact that ~70% of obese people in the US are unfortunately poor. So you’ve got exuberant success priced in, but also real risk to what you can actually achieve in the business.
Tom: Vihari touched on it there. It’s one of the big players in the weight loss drug space. Casey, what about you? Buy or sell?
Casey: I think we’re a hold on Eli Lilly, because I think they’ve really executed incredibly well and they’re the clear market leader in GLP-1s. Their injectable Zepbound is gaining a lot of market share over Novo, which looks set to extend given Novo’s latest next-generation drug CagriSema failed to show superiority. We’re now moving into the era of oral GLP-1s, and Eli Lilly is pursuing the avenue of a small molecule compared to the peptides that Novo is doing, which will be far cheaper, and that’s going to be important because there are probably going to be maintenance-type drugs for many people. There is a lot of success built in, and there is still risk, particularly around their next generation injectable — but the risks are reasonably balanced given they are the market leader.
Walmart (NYSE: WMT)
Tom: Next up is American retail giant Walmart. I think it became a member of the trillion dollar club earlier this year. Casey, I’ll stay with you. Buy, hold, or sell?
Casey: We think Walmart is a sell. It’s an incredibly high quality company. Their customer value proposition is sort of unrivalled and they still have opportunities for share gain. They’re implementing AI to enhance growth in their e-commerce segment and also in advertising and membership. It’s become a bit of a market darling, a defensive haven but also an AI winner. As a result, it’s trading on ~42 times earnings, which is about 15 turns higher than its long-term average. The valuation risk/reward just doesn’t stack up for us at this level.
Tom: I think it’s up over 42% over the last year or so. Vihari, what about you, buy, hold, or sell?
Vihari: Walmart is a sell for me as well. This is again trading on a really high multiple. There’s been all this capital expenditure spent to platform themselves into an e-commerce-style giant, and really all of that money was spent simply to stand still. They still grow revenues at 5% per annum, just like they always did and if they hadn’t spent all that money, they wouldn’t even have been growing that fast. This is a classic example of overvalued quality in our market. Just because everyone says quality underperformed in 2025 and is going to bounce back, the reality is this is extremely overvalued still, and quality as a factor is extremely overvalued. Very much a sell.
ExxonMobil (NYSE: XOM)
Tom: Next up, we have ExxonMobil, probably the biggest story in markets over the last week or two. Vihari, I’ll start with you. Is that a buy or sell?
Vihari: Exxon is more of a hold. We prefer TotalEnergies, which is a French oil major, because Exxon trades at double the multiple of Total. That said, Exxon has had a really good hit rate in terms of execution on projects – they’ve been good capital allocators, have a decent dividend yield, and have pivoted more towards renewables. There is a capital cycle playing out in real assets and oil investment, and Exxon is probably the best management play on that dynamic. But we do prefer Total, which invests more heavily in the gas and hydrocarbon side – they’ve got double the free cash flow yield thanks to that French multiple advantage. Oil in general is a cornerstone of some of those defensive, low volatility investments in our portfolio.
Tom: I think it’s up over 20% already this year. Casey, what about you — buy, hold, or sell on Exxon?
Casey: We’re a sell on Exxon. At Magellan, we only invest in the highest quality companies because they’re the ones that have shown to compound earnings over the long term, and it’s pretty rare that a commodity company meets our quality criteria. Exxon may be one of the better in that space, but over the last 10 years they’ve delivered a return on equity of about 11% , and that’s at a time when you had the massive spike in oil prices during the Ukraine invasion, but also a time when oil prices went negative during COVID. They are advantaged in some of their assets – the Permian and Guyana look pretty good, pretty low cost – but eventually they’re going to deplete. And cyclically right now, I think it’s a pretty bad time to be investing in oil. Oil spiked during the Iranian invasion, and long-term it is oversupplied quite significantly. There’s a lot of spare capacity, demand is still growing but the pace of that growth is slowing as electrification comes through.
Tom: We’ve also asked our guests to bring a large cap pick of their own. Casey, I’ll come back to you. What’s your pick and why?
Visa (NYSE: V)
Casey: Our pick is Visa. It’s not quite in the trillion dollar club – it’s around $600 billion market cap – but we think it can get there in the next few years through a combination of earnings growth and some multiple re-rating. What’s really driving their growth is the transition to digital payments and a cashless society. You may think that’s pretty much run its course if you live in Australia, where penetration is about 87%, but it’s far lower in a lot of developed countries like Germany or Japan where it’s still only 40–50%. In emerging markets it’s a fraction of that in big countries like India and Mexico it’s only 20–30%. So there’s still a really long tailwind for growth in the transactions part of the business.
Then you also have their value-added services, which is a newer, much faster-growing segment where they deliver services to merchants and issuers – things like fraud protection, marketing, card issuance and tokenisation. That’s only about 20% of their business now, but it’s growing at about 28% and has a really long runway. Overall, the business can compound at mid-teens growth levels. The stock has been hit from a valuation point of view due to negative sentiment around stablecoins and potential caps on credit card interest rates – we think neither will come to pass in any meaningful way. With the stock trading near trough levels, there’s potential for re-rating as that sentiment starts to improve.
Walt Disney Co (NYSE: DIS)
Tom: So it’s Visa from Casey. Vihari, what have you got for us?
Vihari: For me I’m going to go with one that everyone’s going to know the name of, but might not have thought of as an investment, and that is Disney. Disney is very much priced like a legacy, old-world media company with a declining linear cable platform. But the reality of the business is very different. They’re getting almost 60% of their earnings from experiences – the theme parks, the cruises, the resorts – and that’s the cash cow that sits within the business. In addition, the decline in linear is being replaced rapidly with growth in direct to consumer through ESPN, HBO Max and Disney+. As that bundling dynamic plays out in direct-to-consumer, you’re getting much better customer lock-in, pricing power, and a real profitability inflection. You’re essentially paying 14–15 times – a discount to history when the company was at its prime – for a business that’s going to have an earnings inflection and grow at 15% per annum. I like that one.
Tom: There you have it – seven large caps that aren’t the Mag 7. Thanks to Casey and Vihari, and thanks for watching. Make sure to check out our YouTube channel for more.
Subscribe to receive the latest news and insights from the Antipodes team


